Solvay Announces Strategic Collaboration with Ginkgo Bioworks and Expands its R&I Footprint in The United States
Solvay, a leading science and materials company whose technologies bring benefits to many aspects of daily life, announced a strategic collaboration with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity.
Through this multi-year strategic collaboration agreement, Solvay will join forces with Ginkgo to unlock the power of synthetic biology as an enabler of more sustainable chemicals and materials, contributing to the transition towards more environmentally-friendly solutions. This alliance will start by focusing on new sustainable biopolymers, specialties which could tangibly impact a breadth of markets, from home and personal care to agriculture and food.
As part of this partnership, Solvay will also acquire a Ginkgo (formerly Zymergen) laboratory in Cambridge, Massachusetts. This acquisition will expand Solvay’s research and innovation (R&I) footprint in the US, provide Solvay access to new talents, and establish a sustainable growth base in synthetic biology in one the most important biotech hubs in the world, accelerating the company’s biotech development plan.
With this strategic collaboration and expansion, Solvay will integrate deep competencies in bioinformatics and data science, strain engineering, biocatalysis and fermentation processes, strengthening and accelerating the ability to scout, develop and turn into businesses the most valuable biotech-enabled opportunities.
This partnership is designed to strengthen Solvay’s position in biotechnology as part of the Renewable Materials and Biotechnology growth platform which aims to meet growing demand for sustainable solutions by increasing the share of renewable carbon in Solvay’s product offering and developing new business opportunities enabled by biotechnology. This growth platform complements the company’s activities in three other key areas: battery materials, green hydrogen and thermoplastic composites.
Ilham Kadri, Solvay CEO said:
We’re thrilled to make this important investment and to partner with Ginkgo Bioworks on an exciting project to develop sustainable chemicals and materials, allowing us to provide innovative biotechnologies to new markets.
“Biotech is the future and this step is an important milestone for our growth platform. We expect to leverage our new presence in the Boston area to step up and accelerate our offerings in this field.”
Jason Kelly, CEO and co-founder of Ginkgo Bioworks, said:
We’re so excited to welcome Solvay to our platform and to the Boston area at such a pivotal growth period for both of our companies.
“In our case, it’s fantastic to be able to integrate platform capabilities from Zymergen and make them accessible to our partners so quickly”.
“Synthetic biology can help companies across a wide breadth of markets reach their environmental and economic goals at the same time, and it’s thrilling to work with a partner taking such a big swing at sustainability.”
Solvay is a science company whose technologies bring benefits to many aspects of daily life. With more than 22,000 employees in 61 countries, Solvay bonds people, ideas and elements to reinvent progress. Solvay seeks to create sustainable shared value for all, notably through its Solvay One Planet roadmap crafted around three pillars: protecting the climate, preserving resources and fostering a better life.
The Group’s innovative solutions contribute to safer, cleaner, and more sustainable products found in homes, food and consumer goods, planes, cars, batteries, smart devices, health care applications, water and air purification systems. Founded in 1863, Solvay today ranks among the world’s top three companies for the vast majority of its activities and delivered net sales of €13.4 billion in 2022. Solvay is listed on Euronext Brussels and Paris (SOLB). Learn more at www.solvay.com.